Investing

Aurinia Pharmaceuticals : AUPH

AUPH

Stock Data

$15.35

$0.04 (0.23%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

Aurinia Pharmaceuticals Inc is a biopharmaceutical company based in Edmonton, Canada, dedicated to the development and commercialization of treatments for diseases lacking sufficient medical solutions. Its flagship product, LUPKYNIS, is designed for adults with active lupus nephritis, showcasing the company's focus on addressing significant unmet medical needs. Aurinia Pharmaceuticals also collaborates with Otsuka Pharmaceutical Co., Ltd., highlighting its commitment to expanding its impact and reach in healthcare.

All Aurinia Pharmaceuticals Articles

3 Articles

Trey Thoelcke | Aug 7, 2025 at 8:45 AM EDT

Berkshire Hathaway Picks Up More of Warren Buffett’s Favorite Media Stock

Berkshire Hathaway has resumed acquiring shares of Warren Buffett's favorite media stock. Other insider buyers are focused on three biotech…

Trey Thoelcke | Mar 11, 2025 at 8:45 AM EDT

Insiders Are Loading Up on These 4 Biotech Stocks Now

Officers, beneficial owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks…

Trey Thoelcke | Dec 15, 2024 at 8:20 AM EST

Insiders Are Loving These 6 Stocks Right Now

The most notable insider purchases of stock in the past week were in biotech and energy companies, as well as…